JAMA Network
About The Study: This phase 3 randomized controlled trial found that gefurulimab (once-weekly, self-administered injection) provided significant early and sustained clinical benefits for adults with generalized myasthenia gravis. Results showed meaningful improvements in daily living and muscle strength scores compared to placebo at week 26, and most side effects were mild, with similar incidence between treatment and control groups.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
